Angiofensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease
References (24)
- et al.
Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition
Brain Res.
(1990) - et al.
Angiotensin II inhibits the release of [3H]angiotensin II from rat enlorhinal cortex ‘in vitro’
Brain Res.
(1989) - et al.
The ACE inhibitor [3H]SQ29.852 identifies a high affinity recognition site in the human temporal cortex
Brain Res. Bull.
(1990) A rapid and sensitive method for the quantilation of microgram quantities of protein utilising the principle of protein-dye binding
Anal. Biochem.
(1976)- et al.
The effect of AC E inhibitors captopril and SQ29.852 in rodent tests of cognition
Pharmacol. Biochem. Behav.
(1989) - et al.
Effects of captopril and SQ29,852 on anxiety-related behaviours in rodent and marmoset
Pharmacol. Biochem. Behav.
(1990) - et al.
Immunohisto-chemical evidence for the existence of angiotensin 11-containing nerve terminals in the brain and spinal cord in the rat
Neurosci. Lett.
(1976) - et al.
Brain renin: localization in rat brain synaptosomal fractions
Brain Res.
(1981) - et al.
Localization of renin (EC 3.4.23) and converting enzyme (EC 3.4.15.1) in nerve endings of rat brain
Brain Res.
(1985) - et al.
Angiotensin converting enzyme in Alzheimer's disease: Increased activity in caudate nucleus and cortical areas
J. Neurochem.
(1982)
ACE inhibition and cognition
Characterisation of [3H]ceranapril recognition sites in rat and human brain tissue
Neuropharmacology
Cited by (128)
Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors
2019, Neuroscience ResearchThe association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer's disease: A meta-analysis
2016, Journal of Clinical NeuroscienceAngiotensin converting enzyme serum activities: Relationship with Alzheimer's disease
2016, Brain ResearchCitation Excerpt :The permeability of the blood brain barrier (BBB) could increase by factors such as age, hypertension, sustained disease,including advanced AD (Starr et al., 2009), and the systemic ACE may enter the central RAS through the BBB, and brain ACE may increase the ACE level in peripheral blood by entering into the blood circulation (Akatsu et al., 2011). Moreover, ACE was shown to increase in AD brain (Arregui et al., 1982; Barnes et al., 1991; Miners et al., 2008; Miners et al. 2009; Savaskan et al., 2001), and it may correlated with the stage of disease (Miners et al. 2009). Meanwhile, our present study showed that serum ACE activity in AD patients was significantly higher than non-AD subjects, and the latter was associated with the severity of the development of AD.
Role of angiotensin receptor blockers in the context of Alzheimer's disease
2023, Fundamental and Clinical Pharmacology
- ∗
Present address: Department of Pharmacology, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.